Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.

ABSTRACT:

Objectives

One of the most significant features of poor prognosis in COVID-19 is pulmonary fibrosis. Nintedanib is a new antifibrotic agent that interferes with processes of pulmonary fibrosis. This study aimed to investigate the efficacy and safety of nintedanib in COVID-19.

Methods

This was an interventional study in which adult patients with COVID-19 requiring mechanical ventilation were consecutively enrolled. The primary endpoint was 28-day mortality after the initiation of mechanical ventilation. The secondary endpoints were length of mechanical ventilation, volume of lung injury, and the incidence of gastrointestinal adverse events and acute liver failure.

Results

Thirty patients with COVID-19 underwent nintedanib therapy. We included 30 patients not receiving

SUBMITTER: Umemura Y 

PROVIDER: S-EPMC8146615 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature